# Treatment Strategy for Patients With RA-ILD

> **NCT07643038** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 204 (estimated)

## Conditions studied

- Rheumatoid Arthritis Associated Interstitial Lung Disease

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Rituximab (RTX)
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT07643038
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-20
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643038, "Treatment Strategy for Patients With RA-ILD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*